SPARC may function similar to TGFβ, where signaling is downregulated in cancer cells early in tumorigenesis, but is overexpressed at later stages, thus acting either as tumour suppressor or oncogene, depending on the tumour stage (Wakefield and Roberts, 2002). The gene discussed is SPARC; the disease is neoplasm.